Anthropic Recruits Big Pharma Boss as It Eyes Historic IPO

A Healthcare Power Move

Anthropic, the company behind the Claude AI assistant, has added one of the biggest names in global pharmaceuticals to its board of directors. Vas Narasimhan, the chief executive of Swiss pharma giant Novartis, becomes the seventh member of Anthropic's board, joining a roster that already includes Netflix chairman Reed Hastings and Confluent co-founder Jay Kreps.

Building the Bridge Between AI and Medicine

The appointment caps a six-month blitz by Anthropic into the healthcare sector. The company launched Claude for Life Sciences in October and Claude for Healthcare in January, forging integrations with platforms like Medidata and ClinicalTrials.gov. Major pharmaceutical firms including Sanofi, Novo Nordisk, and AbbVie are already using Claude in their operations.

Earlier this month, Anthropic acquired Coefficient Bio, a New York-based biotech startup with fewer than ten employees, for approximately four hundred million dollars in an all-stock deal. The team, composed largely of former Genentech computational biology researchers, has been absorbed into Anthropic's healthcare division.

A Board Built for Wall Street

Narasimhan is the second board appointment in as many months. In February, Anthropic added Chris Liddell, former chief financial officer of both Microsoft and General Motors, who has direct experience guiding a major company through a stock market flotation. Together, these appointments signal that Anthropic is assembling the governance structure needed for a public listing.

The company is reportedly in discussions with Goldman Sachs and JPMorgan Chase about an IPO targeting October of this year. Anthropic closed a thirty billion dollar funding round in February at a three hundred and eighty billion dollar valuation, and its annualised revenue run rate has surpassed thirty billion dollars, up from roughly nine billion at the end of twenty twenty-five.

What Narasimhan Brings

A Harvard Medical School graduate who became Novartis CEO in twenty eighteen, Narasimhan oversees a company with a twenty-three billion dollar manufacturing investment programme in the United States. His experience navigating complex global regulatory environments could prove invaluable as Anthropic scales its healthcare ambitions and prepares for the scrutiny of public markets.